Personalized Dosimetry Using I-131-Anti-Cd45-Apamistamab (Iomab-B) Prior To High-Dose Myeloablative Radioimmunotherapy For Hematopoietic Stem Cell Transplant (Hct) In Active, Relapsed, Or Refractory Acute Myelogenous Leukemia: Novel Re-Induction And Targeted Conditioning Feasibility And Engraftment Results From The Sierra Trial